XENOGRAFT AND CELL LINE CORE

异种移植物和细胞系核心

基本信息

批准号：
8516644
负责人：
PETER J HOUGHTON
金额：
$ 18.41万
依托单位：
RESEARCH INST NATIONWIDE CHILDREN'S HOSP
依托单位国家：
美国
项目类别：
财政年份：
2013
资助国家：
美国
起止时间：
2013-06-05 至 2018-05-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8516644
关键词：
Biometry Biostatistics Core Blood Cell Line Childhood Childhood Solid Neoplasm Children&apos s Oncology Group Clinic Consultations Data Disease model Drug Evaluation Drug Kinetics Evaluation Reports Ewings sarcoma Experimental Designs Female Freezing Goals Human Individual Instruction Malignant Childhood Neoplasm Modeling Molecular Profiling Mus Neoplasm Transplantation New Agents Paper Patients Pediatric Oncology Group Pharmaceutical Preparations Pharmacodynamics Program Research Project Grants Protocols documentation Publications Publishing Reporting Rhabdomyosarcoma SCID Mice Saint Jude Children&apos s Research Hospital Services Short Tandem Repeat Testing Tissue Banks Tissues Translating Xenograft Model Xenograft procedure base experience osteosarcoma pre-clinical research study sarcoma subcutaneous tumor tumor xenograft

项目摘要

The Xenograft and Cell Line Core (Core B) will provide state of the art molecularly characterized human models representing childhood sarcoma histotypes to be studied in Projects 1-3. Patient derived xenografts (PDX) representing Ewing sarcoma (n=7). Osteosarcoma (n=10) and rhabdomyosarcoma (n=15) and cell lines (n=16) are available for study. Authenticity and validity of lines within the Core have been determined by periodic short tandem repeat (STR) analysis, and molecular profiling. The Core will provide subcutaneous, orthotopic and disseminated disease models as required for individual projects, as well as services listed: 1. Maintain and characterize human xenografts, and maintain frozen stocks of xenografts authenticated by short tandem repeat (STR) analysis. 2. Maintain and characterize cell lines by STR analysis for use in Projects 1-3. 3. To provide a facility for the propagation of xenografts of pediatric solid tumors, for use in all Projects. 4. Provide orthotopic and disseminated xenograft models for secondary testing. 5. Coordinate tumor transplantation and make available tumor-bearing mice for pharmacodynamic and pharmacokinetic studies as required. 6. Coordinate treatment and tissue collection. 7. Undertake drug evaluation studies using standardized protocols, and transfer data to the Biostatics Core. 8. Provide other services (e.g. blood and tissue collection, for PK/PD studies). 9. Assist in planning and experimental design in consultation with the biostatistics Core A. Although this is a new Core, the Core director has over 35 years experience developing and using human tumor xenograft models, and has published 50 papers reporting the evaluation of new agents using these models since 2007. The

异种移植和细胞系核心（核心 B）将提供最先进的分子特征人类模型，代表项目 1-3 中要研究的儿童肉瘤组织型。代表尤文肉瘤的患者来源的异种移植物 (PDX) (n=7)。骨肉瘤 (n=10) 和横纹肌肉瘤 (n=15) 以及细胞系 (n=16) 可用于研究。核心内细胞系的真实性和有效性已通过定期短串联重复 (STR) 分析和分子分析来确定。核心将根据各个项目的需要提供皮下、原位和播散性疾病模型，以及列出的服务： 1. 维持和表征人类异种移植物，并维持通过短串联重复 (STR) 分析验证的冷冻异种移植物储备。 2. 通过 STR 分析维护和表征细胞系，以用于项目 1-3。 3. 提供儿童实体瘤异种移植物增殖的设施，供所有项目使用。 4. 提供原位和播散性异种移植模型用于二次测试。 5. 协调肿瘤移植并根据需要提供荷瘤小鼠进行药效学和药代动力学研究。 6. 协调治疗和组织采集。 7. 使用标准化方案进行药物评价研究，并将数据传输至生物静力学核心。 8. 提供其他服务（例如血液和组织采集，用于 PK/PD 研究）。 9. 与生物统计学核心A协商，协助规划和实验设计。尽管这是一个新的 Core，但 Core 主任拥有超过 35 年开发和使用人类肿瘤异种移植模型的经验，并自 2007 年以来发表了 50 篇论文，报告使用这些模型对新药物的评估。